Viviana Negrón González, MD
Breast Surgery, Residency Program Director

Contact Info
- Department of Surgery
School of Medicine
Medical Sciences Campus
Office A-923 - 787-763-2440
Education
- BS: Biology, Magna Cum Laude, UPR Río Piedras Campus, 1999
- MD: Magna Cum Laude UPR School of Medicine, 2003
- Residency: General Surgery, UPR-Affiliated Hospitals, 2008
- Fellowship: Breast Surgical Oncology, MD Anderson Cancer Cancer, Houston, TX, 2009
Field of Study
Personal Statement
After completing my general surgery residency, I went on to complete a Breast Surgical Oncology Fellowship at MD Anderson Cancer Center. Ever since returning to Puerto Rico, I have been fortunate to be part of the general surgery residency faculty at the Auxilio Mutuo general surgery rotation and the Carolina General Surgery rotation. Since 2018 I have also been the Program Director. My practice is limited to breast disease including benign, disease, and malignancy. I am an advocate of multidisciplinary management for breast cancer patients.
Positions and Honors
Positions:
- Program Director, General Surgery Residency, 2018-currently.
- Associate Professor: University of Puerto Rico, School of Medicine, March 1, 2020-currently.
- Cancer Committee, Hospital Auxilio Mutuo 20I5-currently.
Honors:
- Corynne S. Uhl Award, MD Anderson Cancer Center 2009.
Research
- Experimental Therapeutics for metastatic and triple negative breast cancer- Collaborator, University of Puerto Rico, Medical Science Campus, currently.
Publications
- Negrón-Gonzalez, V, Oh J, Cristofanilli M, Babiera G. Inflammatory Breast Cance1. Ln: Kuerer’s Breast Surgical Oncology. 1st Edition. 2010.
- Pascual-Marrero A, García J, Negrón V, Méndez W. General Surgery Residency Program response plan to Hurricane Maria in Puerto Rico. American College of Surgeons Meeting 2018. Oral Presentation.
- Dominici L, Negron-Gonzalez V, Hunt KK, Valero V, Buzdar AU, Kuerer H. lncidence of Documented Eradication of Breast Cancer in Axillary Lymph node metastases in patients overexpressing human epidermal growth factor receptor 2 treated with neoadjuvant chemotherapy regimens including Tastuzumab. Cancer. April 2010.
- Rivera N, Cabanillas F, Lawrenson L, Negron V, Pavia 0, Bruno M, Echenique M, Pardo W, Santiago K. Results of a novel neoadjuvant chemotherapy (NAC) for breast cancer. Cancer Research 73 (24 Supplement): P3-14-17. March 2014.
- Giraldo-Jimenez M, Cabanillas F, Negron V, Echenique M, Mojica P., Santiago K, Marcial V, Vaquer R and Carlo-Vargas V. Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico. Puerto Rico Health Sciences Journal. 31 (2): 45-51. June 2012.
- Cotto M, Toro J, Carlo V, Bruno M, Pavia 0, Echenique M, Vaguer V, Negron V, Cabanillas F. Comparison of first course Pet scan against fourth -course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC). Journal of Clinical Oncology. 28 (15_suppl): 564-564. May 2010.
- Mayorga-Pérez, I., Mulero-Soto, P., Cruz-De La Rosa, K., Negrón-González, V., Hernandez-Rosa, J., Feneque-Gonzalez, J., Correa-Rivas, M., Abdul-Hadi, A. “Bilateral phyllodes tumor: Case report”, Journal of Pediatric Surgery Case Reports, Volume 101, Feb. 2024.
- Torres-Sanchez, A., Cruz-Colazo, A., Kentzara, O., Rovira, M., Negrón, V., Carlo, V. “Pharmacodynamic neomalors for Rac and Cdc42 inhibitor efficacy”. Abstract submitted American Association of Cancer Research Annual Conferences. San Diego, CA. 2024.